Eric Lefkofsky is one of the reckoned entrepreneurs in Chicago. Prior to investing, Eric is a philanthropist. He attended the University of Michigan and later went back to Michigan University law school where he earned his Juris Doctor.
Eric has co-founded several organizations. In 2001, together with his friend Brad Keywell, they co-founded Inner Working. He also co-founded Thepoint.com. This is an online collective action website. The firm experienced tremendous growth to become Groupon. Groupon is a prominent online market that connects buyers to sellers by way of travel, coupons, activities, goods, and services.
Eric Lefkofsky co-founded the largest medical library known as Tempus lab. This is a system that organizes patients’ data to be used in the treatment of new patients. The precision medicine firm has built and maintained a system that can acquire personalized data and optimized it for use in personalized care. The company primary focus is to organize data for use in the treatment of cancer. Tempus optimizes big data that is analyzed by physicians to set personalized treatment options for their patients.
Eric Lefkofsky was inspired to start Tempus due to availability of medical data. He noticed that important medical data was unutilized. The organizations’ genomic test analyzes RNA, DNA, and proteomic data in order to comprehend a tumour at the molecular level. This information is later used by physicians to develop tailor-made treatment methods for a specific patient. To know more about him click here.
Tempus organizes data by optimizing clinical notes, pathology images, radiology scans to capture data and lab reports. This makes it easier for physicians to understand the clinical context of each patient. The platform is experiencing rapid growth and continues to provide clinicians with updated treatment options.
The company has been receiving funding from various organizations. Eric Lefkofsky said that the funds will be used to fund research that will be used to grow the data. The company’s goal is to develop a system that will bring precision medicine in cancer.